EVOLVERAI
LIVE

Serial Number

98614898

Owner

BIOXCEL LLC

Attorney

Brendan J. Hughes

Filing Date

Jun 24, 2024

Add to watchlist:

No watchlists yet
View on USPTO

EVOLVERAI Trademark

Serial Number: 98614898

EVOLVERAI is a trademark filed by BIOXCEL LLC on June 24, 2024. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

BIOXCEL LLC (4 trademarks)

780 EAST MAIN STREET
BRANFORD, CT 06405

Entity Type: 16

Trademark Details

Filing Date

June 24, 2024

Registration Date

Not Registered

Published for Opposition

June 17, 2025

Goods & Services

Providing online nondownloadable computer software using artificial intelligence for automated machine learning in the field of drug design and development; Providing online nondownloadable computer software using artificial intelligence for collecting, analyzing, interpreting, and reporting data and information for drug design and development; Providing online nondownloadable computer software using artificial intelligence for automated machine learning for drug design and development in the fields of neuroscience and immune-oncology; Providing online nondownloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Providing online nondownloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of neuroscience and immune-oncology; Providing online nondownloadable software for molecular research, research and development of pharmaceutical products and chemical compounds, and analysis of biological or chemical activity in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Providing online nondownloadable artificial intelligence software for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, development, and response prediction in the fields of neuroscience and immuno-oncology; Providing online nondownloadable software using artificial intelligence and incorporating computational methods and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for automated machine learning in the field of drug design and development; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for collecting, analyzing, interpreting, and reporting data and information for drug design and development; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for automated machine learning for drug design and development in the fields of neuroscience and immune-oncology; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of neuroscience and immune-oncology; Platform as a service (PaaS) featuring computer software platforms for molecular research, research and development of pharmaceutical products and chemical compounds, and analysis of biological or chemical activity in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, development, and response prediction in the fields of neuroscience and immuno-oncology; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence and incorporating computational methods and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; Pharmaceutical and biopharmaceutical research and development; Pharmaceutical and biopharmaceutical research and development in the fields of neuroscience and immuno-oncology; Scientific and medical research in the fields of pharmaceuticals, biologic testing and interpretation, neuroscience, and immuno-oncology; Research and development of pharmaceuticals, biological preparations, and therapeutic products and medicines.

Downloadable computer software using artificial intelligence for automated machine learning in the field of drug design and development; Downloadable computer software using artificial intelligence for collecting, analyzing, interpreting, and reporting data and information for drug design and development; Downloadable computer software using artificial intelligence for automated machine learning for drug design and development in the fields of neuroscience and immuno-oncology; Downloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Downloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of neuroscience and immune-oncology; Downloadable computer software for molecular research, research and develop and development of pharmaceutical products and chemical compounds, and analysis of biological or chemical activity in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Downloadable artificial intelligence software for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, development, and response prediction in the fields of neuroscience and immune-oncology; Downloadable software using artificial intelligence and incorporating computational methods and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development.

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 12, 2026 EXRA
SOU EXTENSION 1 GRANTED
Feb 11, 2026 EX1G
SOU EXTENSION 1 FILED
Feb 11, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 11, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 12, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 17, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 17, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 11, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 15, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 18, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 18, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 18, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 18, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 18, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 18, 2025 CNRT
ASSIGNED TO EXAMINER
Jan 14, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 13, 2025 NWOS
NEW APPLICATION ENTERED
Jun 24, 2024 NWAP